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Recent studies indicate that T cell cross-priming preferentially
occurs against long-lived, stable proteins. We have studied cross-
priming by using the glycoprotein (GP) of lymphocytic choriomen-
ingitis virus (LCMV), a protein that normally is not MHC class I
cross-presented. This study shows that a C-terminally truncated,
noncleavable variant of LCMV-GP led to the accumulation of stable,
soluble GP trimers in the endoplasmic reticulum (ER) of the antigen
donor cell, and thereby converted LCMV-GP into a potent immuno-
gen for cytotoxic T lymphocyte cross-priming. Immunization of
mice with tumor cells expressing an ER-retained LCMV-GP variant
cross-primed protective antiviral cytotoxic T lymphocyte responses
in vivo at least 10,000-fold better than immunization with cells
expressing the cross-presentation-‘‘resistant’’ wild-type LCMV-GP.
Thus the ER is a cellular compartment that can provide antigen for
cross-presentation, and modifications affecting stability and sub-
cellular localization of the antigen significantly increase its avail-
ability for MHC class I cross-presentation. These findings impinge
on vaccine strategies.
cross-presentation  cytotoxic T lymphocytes  vaccination 
antigen presentation
CD8 T cells specifically recognize and eliminate infected ortransformed cells that display antigenic peptides on their
surface MHC class I molecules. Induction of strong CD8 T cell
responses is, therefore, a major goal in the development of
preventive and therapeutic vaccines against persistent viruses
and tumors. Most MHC class I positive cells exclusively present
peptides generated during the degradation of endogenously
synthesized proteins. In contrast, professional antigen-
presenting cells (APCs), the key initiators of CD8 T cell
responses (1), can additionally present peptides derived from
exogenous antigens taken up from the extracellular milieu via a
pathway termed cross-presentation (2–4). Cross-presentation is
most efficient for particulate or cell-associated antigens that
target phagocytic uptake by APCs. Antigenic peptides may be
directly generated by endosomal proteases; however, the main
cross-presentation pathway in vivo appears to involve antigen
translocation from the phagosome into the cytosol and degra-
dation by the proteasome (2, 3). Although the mechanisms
governing the uptake and processing of exogenous antigen are
now being elucidated at the molecular level (5–14), much less is
known about whether the nature or subcellular localization of
the antigen influence its ability to enter the cross-presentation
pathway.
One critical parameter limiting the ability of a given antigen
to be cross-presented very likely is its half-life. Indeed, several
recent studies indicate that mature, stable protein represents a
major source of antigen for cross-presentation in vivo. For
instance, cytotoxic T lymphocyte (CTL) responses were found to
be preferentially cross-primed against peptide determinants of
long-lived proteins but not of rapidly degraded signal sequences
(15). Conversely, cross-priming is enhanced by inhibition of
proteasomal degradation of proteins (16). Cross-presentation
was also found not to require antigen neosynthesis by the antigen
donor cell (17). Last, it was shown that the cross-priming antigen
can be removed from cell lysates by depletion of the intact
protein, further suggesting that cross-presented peptides were
derived from stable protein (18). Taken together, these studies
imply that effective vaccines for cross-priming CTL responses
should aim at maximal metabolic stability of the antigen.
We have tested whether this concept could be exploited to
augment cross-presentation of antigens that normally do not
enter the cross-presentation pathway. Previous studies investi-
gating CTL priming against lymphocytic choriomeningitis virus
glycoprotein (LCMV-GP) as a cell-associated antigen (19–21)
have consistently failed to demonstrate a role for cross-
presentation in these responses. Therefore, we attempted to
increase the stability of LCMV-GP and generated a soluble,
noncleavable, and trimer-stabilized GP variant. Our findings
indicate that these modifications not only led to an unexpected
retention and accumulation of the variant protein within the
endoplasmic reticulum (ER) of the antigen donor cell but also
drastically enhanced its potential to enter the cross-presentation
pathway and to induce protective CTL responses in vivo.
Results
A Soluble, Noncleavable Variant of LCMV-GP Is Retained in the ER.
Wild-type (WT) LCMV-GP (Fig. 1A) is translated as a mem-
brane-bound single precursor protein (GPc) into the ER, where
it undergoes folding, glycosylation, and trimerization before ER
export (22, 23). Within the Golgi compartment, the GPc trimers
are proteolytically processed by S1P/SKI-1 (24) into a peripheral
receptor-binding subunit GP-1 and a transmembrane subunit
GP-2 (Fig. 1A). Both subunits stay noncovalently associated and
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form metastable heterodimeric trimers that are exported to the
cell surface, where they become incorporated into budding
virions. Similar to other class I viral fusion glycoproteins,
proteolytically activated GP-1/GP-2 trimers serve two major
functions in the virus life cycle: (i) receptor-binding and virus
uptake is mediated by GP-1, and (ii) viral membrane fusion at
low endosomal pH by GP-2 (25). By following a recently
published approach (22), we have expressed LCMV-GP as a
soluble trimeric complex (GPER, Fig. 1B) by replacing the
transmembrane region and the C-terminal half of GP-2 with a
small trimerization-promoting domain derived from phage T4
fibritin. In addition, we mutated the S1P/SKI-1 protease recog-
nition site to prevent proteolytic activation, and thus conversion
of the trimeric complex into the metastable low-pH-sensitive
conformation. When expressing GPER in murine MC57 fibro-
blast cells we unexpectedly found that the variant protein was not
secreted into the cell culture supernatant, but was retained
intracellularly as stable trimeric complex. Western blot analysis
of cell lysate but not of culture supernatant detected GPER as
a single band migrating between 150 and 250 kDa (Fig. 1C).
Thus, GPER had undergone complete trimerization, and the
GP-1 subunit was correctly folded to allow recognition by the
conformational antibody KL25 (Fig. 1C).
To determine the subcellular location of the retained GPER,
we generated stable MC57 cell lines expressing GPER (MC-
GPER) orWTGP (MC-GP). SubclonedMC-GPER and control
MC-GP were transfected with GFP-KDEL or stained for caln-
exin before immunofluorescence microscopy analysis (Fig. 1
D–O). In contrast to WT GP, which was detectable throughout
the complete secretory pathway (Fig. 1 D and H) and showed
marked cell surface expression (Fig. 1E), GPER completely
colocalized with GFP-KDEL and did thus not reach the medial
Golgi (Fig. 1 G and L–N). Moreover, as we observed GFP-
KDEL-positive sites that were GPER-negative, and because
GPER did not colocalize with COPII (data not shown), we
concluded that GPER was fully retained within the ER. GPER
was predominantly retained in calnexin-positive ER regions,
indicating that it could be associated with chaperones (Fig. 1 F
and L). To further demonstrate that GPER was completely
retained within the ER, we performed a pulse–chase experiment
and tested for endoglycosidase H (Endo H) sensitivity (Fig. 1P).
Because the majority of newly translatedWTGP has left the ER
after 3 h as judged by S1P/SKI-1 cleavage (26), we analyzed the
Endo H sensitivity of GPER 3 h after translation. As expected,
the majority of the control WT GPc was proteolytically pro-
cessed into GP-1 and GP-2, and thus had passed the Golgi,
whereas GPER was uncleaved. GPER and remaining uncleaved
WT GPc were found to be Endo H-sensitive, in contrast to GP-1
and GP-2, which were Endo H-resistant, but peptide-N-
glycosidase F-sensitive. Thus, GPER was completely retained
within the ER and did not reach the Golgi compartment. Finally,
we tested whether ER retention caused increased GPER levels
in the MC-GPER cells compared with WT GP in the MC-GP
cells. Indeed, intracellular retention of GPER resulted in 10-
fold higher total protein levels (Fig. 1Q).
GPER Is a Potent Immunogen for Cross-Priming. MC-GPER did not
differ from MC-GP in the ability to present endogenously
derived GP epitopes via MHC class I, and they were readily lysed
by gp33-specific CD8 T cell lines or primary LCMV-WE-
specific effector CTLs obtained from day 8 infected mice (Fig.
2A). We next tested the ability of MC-GPER to induce CTL
responses in vivo by immunizing C57BL/6 mice with MC-GPER,
and we found a strong priming of GP-specific CTL responses as
determined by enumeration of gp33- and gp276-specific effector
CD8 T cells (Fig. 2B). These effector cells also exhibited a
highly activated phenotype as demonstrated by down-regulation
of CD62L and their ability to cause beta-islet destruction in the
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Fig. 1. C-terminally truncated LCMV-GP is retained within the ER. (A) Cartoon
of full-length WT LCMV-GP. LCMV-GP is translated as a single precursor protein
(GPc) into the lumen of the ER. The leader sequence (L) at the N terminus is
indicated. After transport to the Golgi complex, GPc is cleaved by the protease
S1P/SKI-1 into the peripheral subunit GP-1 and the transmembrane subunit GP-2.
Several features within GP-2 are highlighted: an N-terminal fusion peptide
(green), a central coiled-coil core (dark blue), and a helical region (light blue)
before the transmembrane region (TM). (B) Truncated LCMV-GP fibritin fusion
protein (GPER). The S1P/SKI-1 cleavage site is mutated to avoid proteolytic pro-
cessing, and the C-terminal half of GP-2 is replaced by a trimerization-promoting
fibritin sequence (F). (C) Native Western blot analysis of total cell lysate (CL) and
of concentrated cell supernatant (SN) of MC57 cells stably expressing GPER. (D–O)
Subcellular localization of WT LCMV-GP in stably transfected MC57 cells (MC-GP)
andofGPERinstablytransfectedMC57cells (MC-GPER).GPexpression isdetected
with the GP-1-specific mAb KL25 (red). (D and E) MC-GP transfected with GFP-
KDEL (green) being either permeabilized (D) or nonpermeabilized (E) before
KL25 staining. (F and G) KL25 stained, permeabilized MC-GPER, either costained
with the ER marker calnexin (green) (F) or transfected with GFP-KDEL (green) (G).
(H–O) Triple staining of MC-GP (H–K) and MC-GPER (L–O) with KL25 (red), GFP-
KDEL (green), and calnexin (blue). (Scale bars: 2 m.) (P) HeLa cells transiently
transfected with WT LCMV-GP (GP) or with truncated fibritin fusion protein
(GPER) were radioactively labeled and chased for 3 h before lysis and immuno-
precipitation with the GP-1-specific Ab KL25. Immunoprecipitates were treated
with peptide-N-glycosidase F, treated with Endo H, or left untreated as indicated.
Bands representing the glycosylated or deglycosylated precursor protein (gGPc
or GPc), the glycosylated or deglycosylated GP-1 subunit (gGP-1 or GP-1), the
glycosylatedordeglycosylatedGP-2subunit (gGP-2orGP-2),andtheglycosylated
or deglycosylated truncated GPER fusion protein (gGPER or GPER) are indicated
by arrows. (Q) MC-GPER (black line), MC-GP (gray line), and parental MC57 cells
(gray solid line) as assessed by FACS after intracellular KL25 staining.
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RIP-GP mouse model (19) of T cell-mediated type I diabetes
[see supporting information].
Cells expressing GPER induced CTL via cross-priming as fol-
lows. For this purpose H-2b  H-2d F1 mice were immunized with
H-2b expressing MC-GPER and induction of H-2d-restricted CTL
responses was monitored. GP-specific CTL responses were not
detected in mice immunized with the parental MC cell line;
however, priming with 5 106 MC-GPER induced H-2b-restricted
gp33-specific as well as H-2d-restricted gp283-specific CTL re-
sponses (Fig. 2 C and D). The cross-primed CTL responses were
more easily detected in cells from peritoneal exudates, where
gp283-specific CTLs accumulated to represent 6.3  0.6% of total
CD8 T cells at day 10 after immunization (Fig. 2 C and D).
Although these data indicated that GPER can be cross-presented
in vivo, it might not be valid to compare an immunodominant CTL
epitope with a subdominant CTL epitope to evaluate the efficiency
in CTL priming against epitopes that are either directly presented
by tumors (such as the dominant H-2b epitope gp33) or depend on
cross-presentation by host APCs (such as the subdominant H-2d
epitope gp283). To analyze cross-priming of gp283-specific CTL in
absence of the gp33-specific CTL response, responses were studied
in H-2bxd F1 mice, which are selectively tolerant to gp33. BALB/c
mice (H-2d) were intercrossed with the H8 mouse strain (H-2b),
which ubiquitously expresses the gp33 CTL epitope as a transgene.
As expected, B/cH8 F1 mice immunized withMC-GPER lacked
gp33-specific CTL responses and exhibited slightly increased re-
sponses to another H-2Db-restricted epitope (i.e., gp276). In addi-
tion, B/cH8 F1 mice mounted enhanced CD8 T cell responses
against the cross-presented H-2Kd-restricted gp283 epitope, such
that these cells represented 11.6 3.3% of the peritoneal CD8 T
cells at the peak of the response (Fig. 2 C and D).
Immunization of H-2bxd F1 mice with either MC-GPER or
MC-GP induced the expansion of H-2b-restricted gp33-specific
CTL (Fig. 3) either by direct priming or by cross-priming.
Nevertheless, compared with MC-GPER, a 10-fold higher prim-
ing dose of MC-GP was required, likely reflecting the known
differences in antigen expression by these cell lines (Fig. 1P).
Although the weaker CTL priming with MC-GP could be
compensated with application of higher doses for the induction
of gp33-specific CTL responses, this result was not achieved for
gp283-specific H-2d-restricted CTL responses that depend en-
tirely on cross-presentation. Strikingly, no cross-presentation
was observed even if the number of injected MC-GP was
increased to 5  107 cells (Fig. 3). Thus, in contrast to WT
LCMV-GP, GPER was efficiently cross-presented in vivo.
Cross-Primed CTL Responses Confer Protection Against LCMV Infec-
tion in Mice. We next sought to test the functionality of the
cross-primed CTL responses in a more physiological situation,
and to evaluate their protective capacity against a challenge
infection with LCMV-WE. To exclude any contribution of direct
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Fig. 2. ER-retained GPER is cross-presented in vivo. (A) Lysis of unpulsed
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in peritoneal exudate (C andD Lower) and spleen (DUpper) on days 7, 10, and
13 (d7, d10, and d13) after immunization was measured after in vitro restimu-
lation for 6 h with the indicated peptides. (C) FACS plots of peritoneal exudate
cells from individual mice on day 10. (D) Spleen cells (Upper) and peritoneal
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circles, MC-GPER-immunized CB6 F1 mice; shaded circles, MC-GPER-
immunized B/cH8 F1 mice. Mice infected with GP-recombinant vaccinia virus
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priming by the tumor cell itself, we injected the H-2b MC-
GPER into H-2d BALB/c recipient mice. Immunization of
BALB/c mice with MC-GPER primed gp283-specific CTL re-
sponses, to a comparable extent as that observed after infection
with a recombinant vaccinia virus expressing LCMV-GP (VV-
G2; Fig. 4A). Although low in frequency at 15 days after
immunization, the gp283-restricted CTLs expanded drastically
after challenge infection with LCMV-WE and were able to
confer full protection against this virus (Fig. 4 B–E). We could
exclude that the gp283-specific CTL response reflected a pri-
mary response induced by the LCMV challenge infection rather
than a secondary response of cross-primed CTL induced by
tumor cells. Immunization of the mice showed no CTL responses
against the LCMV nucleoprotein-derived np118 epitope, which
is the immunodominant H-2d epitope. In addition, specific CTL
were not detected at this time point in mice receiving virus
challenge alone (Fig. 4 D and E). Four days after infection,
spleens of MC-GPER primed mice were free of virus and
contained high numbers of cytokine producing gp283-specific
CD8T cells that lysed gp283-labeled target cells directly ex vivo.
Furthermore, cross-primed gp283-specific CTL induced by MC-
GPER immunization protected against LCMV infection not
only during the effector phase (day 15 after immunization) but
also during thememory phase (day 41 after immunization) of the
immune response (Fig. 4B). A contribution of CD4 T cell
responses to antiviral protection could be excluded because
tumor cells and virus replication were controlled in CD4 T
cell-depleted animals (Fig. 4B). Thus, immunization with cells
expressing ER-retained GPER cross-primed strong CTL re-
sponses that protected against infection with LCMV-WE.
Modifications of GPER Determine Cross-Priming Potential.Given that
other studies failed to demonstrate cross-priming after immu-
nization with tumor cells expressing full-length WT LCMV-GP
(20, 21), we set out to determine whether it was the altered
stability and subcellular localization, or the total quantity of
GPER, that enabled cross-presentation. To address this ques-
tion, BALB/c mice were immunized with titrated numbers of
MC-GP or MC-GPER. CTL responses were analyzed by their
ability to produce cytokines, to lyse target cells directly ex vivo,
and to protect against in vivo challenge with a low-dose infection
of LCMV-WE (Fig. 5). Consistent with the observations of
others (20, 21), we found that MC-GP cells expressing WT
LCMV-GP did not cross-prime CTL responses, and conse-
quently failed to provide protection against challenge infection.
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indicated(opencircles).CD4-depleted(opendiamonds)animalswere immunized
with MC-GPER and challenged 15 days later with LCMV-WE. (C–E) Ex vivo cyto-
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and np118-specific CD8 T cells in spleens on day 4 after virus challenge.
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In contrast, antiviral protection after immunization with MC-
GPER was consistently observed at a priming dose of as few as
50,000 cells, and could be detected even in a subset of the animals
immunized with 5,000 cells (Fig. 5A). Spleens of these mice also
contained LCMV-GP-specific cross-primed CTLs capable of
cytokine production and of lysing gp283-labeled targets directly
ex vivo (Fig. 5). These data demonstrate that GPER-expressing
cells were at least 1,000- to 10,000-fold more potent at inducing
CTL cross-priming than WT GP-expressing cells. Our earlier
data showed that GPER is expressed at 10-fold greater levels
than WT LCMV-GP in murine fibrosarcoma cells (Fig. 1P).
Therefore, the enhanced cross-presentation potential of GPER
not only was determined by the increased antigen dose but very
likely resulted from the modifications affecting its solubility,
stability, and subcellular localization.
Discussion
We have previously performed extensive studies of CTL priming
against cell-associated LCMV-GP without detecting a contribu-
tion of cross-presentation to the induction of GP-specific CD8
T cells in response to GP-expressing fibroblasts (20, 21) or
splenocytes derived from GP-transgenic mice (21). In addition,
and in contrast to similar studies employing other model anti-
gens, such as ovalbumin (27, 28), LCMV-GP is also not cross-
presented when expressed in pancreatic islet cells (19, 29). In the
present study we show that the normally cross-presentation-
‘‘resistant’’ LCMV-GP can be converted into a potent antigen for
CTL cross-priming by several modifications that affect the
solubility and stability of the trimeric GP complex, its subcellular
localization, and the quantity expressed on a per-cell basis.
The variant GPER differed from the WT GP by its lack of a
transmembrane domain, the addition of a phage-derived
trimerization-promoting domain, and by its resistance to pro-
cessing into metastable GP-1/GP-2 complexes because of a
mutated protease cleavage site. Although all of these modifica-
tions very likely have increased the stability of the GP trimeric
complex, they also led to the retention and accumulation of the
variant protein within the ER. Because the capacity of both
proteins to cross-prime CTL represented a difference of 3–4
orders of magnitude, the increased CTL cross-priming efficiency
of GPER cannot be attributed to the accumulation of 10-fold
higher protein levels alone. Instead, both the presence of soluble,
noncleavable, and trimer-stabilized GP complexes and the pro-
tein’s retention in the ER are likely to be responsible for its
acquired ability to be cross-presented.
Cross-presented antigens are preferentially long-lived pro-
teins (15–18). Presumably GPER formed stable, soluble trimeric
complexes that might survive longer in the endosomal pathway
of the APC, which in turn could increase the chance of trans-
location of sufficient amounts into the cytosol for antigen
processing and cross-presentation. That degradation in the APC
phagosome critically limits the availability of protein for cross-
presentation is illustrated by the observation that blocking
phagosome acidification enhances CTL cross-priming in vivo
(30). Importantly, the proteolytically activated GP-1/GP-2 com-
plexes of WT GP dissociate on endosomal acidification (25) and
expose the N-terminal sequences of GP-2 containing the gp283
epitope. Premature degradation of this CTL epitope may there-
fore be limited or prevented in noncleavable GPER where gp283
remains buried in the interior of the GP-1/GP-2 complex. In
addition to its increased stability, the ER retention of GPERmay
have also promoted cross-presentation. Although both cell
membrane-bound WT GP and ER-retained GPER would be
phagocytosed as cell-associated antigens, accumulation of
GPER within the ER could enhance cross-presentation by
providing the antigen in a more concentrated manner. Further-
more, it is conceivable that, on cell death, the GPER might be
enclosed within ER-derived membranes or vesicles that could
further protect the protein from rapid degradation within the
endocytic pathway. Yet another aspect of ER retention should
be considered. Although GPER had trimerized and folded
overall correctly to generate the conformational GP-1 epitope
detected by the antibody KL25 (see Fig. 1C), the observed
ER-retention phenotype was likely caused by some minor fold-
ing and/or export defect. This phenotype, in turn, would lead
to reassociation with chaperones, which has been reported
to enhance delivery of proteins and peptides to APCs for
cross-presentation (12, 17). In addition, misfolded proteins are
retrotranslocated into the cytosol and destroyed via the ER-
associated degradation pathway (ERAD) (31). Thus, GPER-
expressing donor cells may contain higher numbers of antigenic
peptides derived from continuous degradation of misfolded and
accumulated protein.
Finally, our observations may also signify a more general phe-
nomenon. Although CTL cross-priming was not observed for
LCMV under WT conditions, other virus infections may well
induce overexpression and accumulation of viral proteins in theER,
and thus trigger the ER-stress response (32). While this cellular
response to unfolded proteins is known to assist protein folding by
up-regulating molecular chaperones, it may also promote apoptosis
of infected cells after prolonged exposure to ER stress (33). In view
of our data, it is tempting to speculate that viral proteins accumu-
lating in the ER of infected cells undergoing ER stress-triggered
apoptosis could be used by the immune system as a source of
antigen for cross-presentation. Thus, the ER quality control might
be linked to antigen cross-presentation via the ER stress response,
in a manner similar to that already recognized for direct MHC I
presentation via the ERAD.
In summary, our findings identify the ER as a cellular
compartment that efficiently provides antigen for CTL cross-
presentation, and they show that modifications affecting the
stability and subcellular localization of an antigen can drastically
enhance its delivery into the cross-presentation pathway.
Materials and Methods
Cell Lines and Constructs. All cell lines were originally obtained
from the American Type Culture Collection (ATCC) (Manassas,
VA). LCMV-GP constructs were prepared by using a full-length
human codon-optimized GP sequence provided by D. von Laer
(34). GPER is composed of amino acids 1–353 of LCMV-GP
with a mutated SKI-1/S1P cleavage site (R262A; ref. 24) fused
to the phage T4-derived fibritin sequence GYIPEA-
PRDGQAYVRKDGEWVLLSTFL (35).
Immunofluorescence Microscopy. The monoclonal antibody KL25
(36), the polyclonal -calnexin rabbit serum (37), and the
GFP-KDEL expression plasmid (38) have been described. Cells
were fixed with 2% formaldehyde, blocked and permeabilized
for 20 min with 10% goat serum/5% FCS/10 mM glycine/0.05%
saponin in PBS, followed by staining with primary antibodies
(KL25 at 10 g/ml and anti-calnexin serum at 1:1,000) for 2 h.
Cells were washed, and stained with secondary antibodies
(anti-rabbit IgG AlexaFluor 647, anti-rabbit IgG AlexaFluor
488, and anti-mouse IgG AlexaFluor 594; all from Molecular
Probes, Invitrogen, Basel, Switzerland; at 1:400) for 45 min.
Coverslips were rinsed with water and mounted with Immu-
Mount (Thermo Shandon, Pittsburgh, PA). Images were re-
corded with a confocal microscope (model LSM510 m; Zeiss,
Feldbach, Switzerland) equipped with a 100/1.40 Plan-
Apochromat objective.
Pulse–Chase. Transfected HeLa cells were starved for 2 h with
DMEM lacking methionine and cysteine, labeled with 72 Ci/ml
[35S]methionine/[35S]cysteine (1 Ci 37 GBq) for 30 min, washed,
and then chased for 3 h with normal medium. Cells were lysed (1%
Triton X-100), nonsoluble material was removed by centrifugation,
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and supernatants were incubated overnight with protein A-
Sepharose and KL25 at 4°C. Peptide-N-glycosidase F and Endo H
were used as described by the supplier (New England Biolabs,
Frankfurt am Main, Germany). Samples were reduced and ana-
lyzed by SDS/PAGE on 10–16% polyacrylamide gels, followed by
phosphorimaging using a BAS 1500 (Fuji, Tokyo, Japan) for
35S-labeled proteins.
Mice and Viruses. C57BL/6 mice, 318 TCR-transgenic mice (39),
RIP-GP mice (19), and H8 mice (40) were bred at the Institut
fu¨r Labortierkunde, University of Zurich. BALB/c (H-2d) mice
and CB6F1 (H-2bxd) mice were from Harlan (Horst, The Neth-
erlands). BALB/c and H8 mice were crossed to obtain B/cH8
F1 (H-2bxd) mice. All animal experiments were performed
according to institutional guidelines and Swiss federal regula-
tions, and were approved by the veterinary office of the Kanton
of Zurich. T cell responses of tumor-immunized mice were
assessed in peritoneal exudate cells and spleens. For challenge
experiments, tumor-primed mice were infected intravenously
with 200 pfu of LCMV-WE as indicated. After 4 days, spleens
were collected for analysis of T cell responses and virus titers
(41). RIP-GPmice (19) were injected with tumor cells or LCMV,
and blood glucose concentration was monitored by using a
Glucometer Elite (Bayer, Zurich, Switzerland). LCMV-WE was
propagated on L929 cells. Vaccinia virus expressing the full-
length LCMV-GP (VV-G2) was propagated on BSC40 cells.
Native Western Blotting. GPER complexes were assessed in MC-
GPER cell lysates and in 40-fold concentrated cell supernatant.
Cells were disrupted in lysis buffer (1% octyl glucopyranoside/0.15
M NaCl in PBS) by Dounce homogenization. Samples were not
heated and were separated by SDS/PAGE under nonreducing
conditions, blotted onto nitrocellulosemembranes, and detected by
using KL25 (5 g/ml) followed by secondary HRP-coupled goat
anti-mouse IgG1 (Zymed, San Francisco, CA).
Flow Cytometry Staining. Lymphocytes were stained with H-2Db/
gp33 or H-2Db/gp276 tetramers in FACS buffer (FB  PBS/2%
FCS/20 mMEDTA) for 10 min at 37°C. Then anti-CD62L-FITC
and anti-CD8a-APC (both BD Pharmingen, Basel, Switzerland)
were added, and staining continued at 4°C for 30 min. Cells were
washed, fixed (FACS Lysis Solution, BD Pharmingen), and
analyzed on a FACSCalibur (BD Biosciences, Basel, Switzer-
land) by using the CellQuest software. To assess GP expression,
106 fixed tumor cells were permeabilized in permeabilization
buffer (PB  FB containing 0.1% wt/vol saponin) for 5 min at
4°C, washed, and stained with KL25 in PB at 4°C for 60min. Cells
were then washed, and bound antibody was detected by FITC-
labeled goat anti-mouse IgG (BD Pharmingen).
Intracellular Cytokine Staining. Spleen cells or peritoneal exudate
cells were cultured in IMDM containing 5 g/ml brefeldin A,
50 units/ml IL-2, 10% FCS, and antibiotics for 6 h at 37°C,
either with or without specific peptide (106 M). Cells were
first stained with anti-CD8a-PE (BD Pharmingen) for 20 min
at 4°C, then fixed with 4% paraformaldehyde for 5 min at 4°C,
permeabilized with PB for 5 min at 4°C, and stained with
anti-mouse IFN-APC and anti-mouse TNF-FITC (both BD
Pharmingen) in PB for 60 min at 4°C. After three washes, cells
were resuspended in FB and analyzed by f low cytometry as
stated above.
CTL Assay. Cytotoxic T cell responses in spleens of tumor- and
virus-primed mice were tested against peptide-pulsed and non-
pulsed 51Cr-labeled P815 (H-2d) cells in a standard chromium-
release assay directly ex vivo. Direct MHC class I presentation of
GP-derived CTL epitopes by GP-expressing cells was tested by
using LCMV-specific CTLs as effectors and 51Cr-labeled tumor
cells as targets either with or without pulse with gp33 peptide.
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